I already did, and the opinion I got is that unless this drug can show the levels of proteinuria reductions (>50%) and complete/partial remission rates seen with standard of care immunosuppression like steroids, the dimx drug may have limited use. We already know this is a class of drug ccr2 I, that doesn’t have good track record and been shown to be a bit mediocre in kidney diseases with proteinuria.
Ann: Investor Presentation, page-109
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.0¢ |
Change
0.010(2.38%) |
Mkt cap ! $239.6M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 44.0¢ | 40.5¢ | $705.9K | 1.678M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 113371 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 1375 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |